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Abstract
Although heterotypic secondary infection with dengue virus (DENV) is associated with severe disease, the majority of
secondary infections are mild or asymptomatic. The mechanisms of antibody-mediated protection are poorly understood. In
2010, 108 DENV3-positive cases were enrolled in a pediatric hospital-based study in Managua, Nicaragua, with 61 primary
and 47 secondary infections. We analyzed DENV-specific neutralization titers (NT50), IgM and IgG avidity, and antibody titer
in serum samples collected during acute and convalescent phases and 3, 6, and 18 months post-infection. NT50 titers
peaked at convalescence and decreased thereafter. IgG avidity to DENV3 significantly increased between convalescent and
3-month time-points in primary DENV infections and between the acute and convalescent phase in secondary DENV
infections. While avidity to DENV2, a likely previous infecting serotype, was initially higher than avidity to DENV3 in
secondary DENV infections, the opposite relation was observed 3–18 months post-infection. We found significant
correlations between IgM avidity and NT50 in acute primary cases and between IgG avidity and NT50 in secondary DENV
infections. In summary, our findings indicate that IgM antibodies likely play a role in early control of DENV infections. IgG
serum avidity to DENV, analyzed for the first time in longitudinal samples, switches from targeting mainly cross-reactive
serotype(s) to the current infecting serotype over time. Finally, serum avidity correlates with neutralization capacity.
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Introduction
The four serotypes of the flavivirus dengue virus (DENV1–4)
cause the most common mosquito-borne viral disease in humans
worldwide, with 50–100 million people infected annually and over
3 billion people at risk [1]. DENV infection can be asymptomatic
or cause a spectrum of disease ranging from classical dengue fever
(DF) to more severe, life-threatening forms termed dengue
hemorrhagic fever (DHF) and dengue shock syndrome (DSS)
[2]. Approximately 500,000 dengue patients require hospitaliza-
tion annually, of whom a large proportion are children [3].
Although several antiviral and vaccine candidates are in various
phases of preclinical and clinical evaluation, current treatment
remains supportive care [4].
The immune response to primary (1u) DENV infection is
characterized by an early IgM response followed by an IgG response
with predominantly IgG1 and IgG3 subclasses [5]. Naı̈ve B cells are
stimulated and develop into DENV-specific B cells, which either
differentiate into memory B cells (MBCs) residing in the secondary
lymphoid organs or into plasma cells (PCs) secreting antigen-specific
antibodies (Abs). Short-lived PCs are active during acute infection,
while long-lived PCs (LLPCs) migrate to the bone marrow and are
responsible for long-term humoral immunity [6,7]. MBCs, which
retain antigen-specific Abs at their surface, and LLPCs, which secrete
antigen-specific Abs, undergo affinity maturation, and only clones
bearing Abs with the highest affinity survive long-term [8]. This process
takes several weeks after acute infection and continues despite the
absence of circulating antigen. During a secondary (2u) DENV
infection, MBCs are rapidly activated [9,10]. Prior DENV infection
provides robust immunity against the homotypic DENV serotype
[11,12]. In contrast, 2u heterotypic infections are associated with a
higher incidence of DHF/DSS, possibly attributable in part to
antibody-dependent enhancement (ADE), where pre-formed Abs to
the 1u infecting serotype bind but do not neutralize the 2u infecting
serotype, instead facilitating an increase in viral uptake by Fcc-receptor
bearing cells [13]. In addition to ADE, cross-reactive T cells formed
during the 1u DENV infection can be over-activated, potentially
contributing to dengue pathogenesis [14,15]. However, the vast
majority of 2u DENV infections are asymptomatic or only result in
mild disease [16], suggesting a protective immune response [17].
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DENV neutralization requires sufficient levels of neutralizing
Abs and the number of Abs bound to a single virion to exceed the
threshold of enhancement, which depends on antibody avidity and
the accessibility of epitopes on the virus particle [18]. The avidity
of anti-flavivirus monoclonal Abs (MAbs) was shown to positively
correlate with neutralization activity in vitro [19], consistent with
lower neutralizing activity observed with MAbs with lower affinity
against variant genotypes within a single DENV serotype [20,21].
However, the relation between neutralizing activity and polyclonal
serum avidity is still unclear [9,22]. Measurement of IgG avidity
has been shown to discriminate between 1u and 2u DENV
infection in polyclonal serum [23–25] but has not been followed
longitudinally.
In this study, we analyzed the DENV-specific neutralization
capacity and IgM and IgG avidity to DENV of serum samples
from our hospital-based study in Managua, Nicaragua. In
Nicaragua, one DENV serotype tends to dominate for several
years, while other DENV serotypes co-circulate at lower levels.
DENV3 was the dominant serotype in 2008–2011 [26]. Prior to
this, DENV2 was the predominant serotype between 1999 and
2002 and between 2005 and 2007 [27–29], while DENV1
predominated between 2002 and 2005 [30]. DENV4 only
circulates at a low level in Nicaragua [31]. We studied both 1u
and 2u DENV infections from the acute phase until 18 months (m)
post-infection. In 2u infections, we measured neutralizing Ab titers
and avidity to DENV3, the currently infecting serotype, and to
DENV2, the most prevalent previously circulating serotype and
our prototype to assess cross-reactive responses and cross-
protection [9,28]. As both Ab concentration and avidity can play
a significant role in virus neutralization [32], we tested possible
correlations between IgM and IgG avidity to DENV, total Ab titer
and DENV-specific neutralization titer.
Materials and Methods
Ethics statement
The protocol for this study was reviewed and approved by the
Institutional Review Boards (IRB) of the University of California,
Berkeley, and the Nicaraguan Ministry of Health. Parents or legal
guardians of all subjects provided written informed consent, and
subjects 6 years of age and older provided assent.
Study population and laboratory tests
Design and execution of the study, inclusion criteria for the
study population, and laboratory tests for confirmation of DENV
infection in patients have been previously described [9,33]. Briefly,
study enrollment occurred in the Nicaraguan National Pediatric
Reference Hospital, Hospital Infantil Manuel de Jesús Rivera
(HIMJR), in Managua from August 1, 2010, to January 31, 2011,
during the peak dengue season. Inclusion criteria included age
between 6 m and 15 years of age. Samples were collected for 3
consecutive days after enrollment (acute), 14–28 days after onset of
symptoms (convalescent), and at 3 m, 6 m and 18 m post-illness.
DENV infection was confirmed by reverse transcription–polymer-
ase chain reaction (RT-PCR) amplification of viral RNA [34];
isolation of DENV in C6/36 Aedes albopictus cells [27]; serocon-
version of DENV-specific IgM Abs as measured by IgM capture
enzyme-linked immunosorbent assay (ELISA) between acute-
phase and convalescent-phase serum samples [35]; and/or a $4-
fold increase in total Ab titer, as measured by Inhibition ELISA
[30,36], between paired acute- and convalescent-phase serum
samples as previously described [26]. 1u and 2u DENV infections
were defined by an Ab titer by Inhibition ELISA of ,10 or $10 in
acute-phase samples, respectively, and/or ,2,560 or $2,560 in
convalescent phase samples, respectively [31,37]. The total Ab
titer was measured only during the acute and convalescent phases
of the infection, as it decreases substantially thereafter.
Viruses and cell lines
DENV was propagated in Aedes albopictus C6/36 cells as
previously described [9]. Cell supernatants were concentrated by
centrifugation through Amicon filters (50 kDa, 3,2506g for
20 min at 4uC) or by ultracentrifugation (90,0006g for 2 h at
4uC, Beckman SW28) and resuspended in PBS. DENV2 (strain
N172, passage 3) and DENV3 (strain N7236, passage 3) are
clinical strains from Nicaraguan patients isolated in the National
Virology Laboratory in Managua and passaged minimally. Raji-
DC-SIGN-R cells (gift from B. Doranz, Integral Molecular,
Philadelphia, PA) were grown in RPMI-1640 medium (Invitrogen)
with 5% FBS at 37uC in 5% CO2 for use in neutralization assays
[38,39].
Neutralization assay
Serum samples were heat-inactivated at 56uC for 20 min and
then diluted in RPMI-1640 with 10% FBS at pH 8.0 using eight
3-fold dilutions (1:10–1:21,870). Neutralization was assessed by
flow cytometry using GFP-expressing DENV reporter virus
particles (RVPs) as previously described [38,39]. The percent
infection for each serum dilution was calculated in relation to the
no-serum control. Data were expressed as percent infection versus
log10 of the reciprocal serum dilution and fitted to a sigmoidal
dose-response curve using GraphPad Prism 5 software (La Jolla,
CA) to determine the titer of Ab that achieved a 50% reduction in
infection (50% neutralization titer, NT50), which is expressed as
the reciprocal of the serum dilution.
Avidity assay
Serum avidity was measured using a modified ELISA protocol
with urea washes [22,23]. DENV3 N7236 was used at a 1:300
dilution (3.46104 pfu/ml), which yielded an OD of 1.0 using
WHO polyvalent serum. To standardize the amount of DENV2
Author Summary
Dengue is the most common mosquito-borne viral illness
in humans, with 3 billion people at risk for infection. Four
different dengue virus serotypes (DENV1–4) cause the
disease, which can be either inapparent or present with
flu-like symptoms (Dengue Fever, aka ‘‘breakbone fever’’).
The disease can be more severe and sometimes fatal, with
signs of bleeding and vascular leakage leading to shock
(Dengue Hemorrhagic Fever/Dengue Shock Syndrome).
No specific treatment or vaccine is available. Understand-
ing how the human immune response develops during a
natural infection can be beneficial for future vaccine
studies and trials. DENV-specific serum neutralizing capac-
ity may play a role in protection. The neutralization
capacity of the serum may depend on the serum avidity
against DENV, the amount (or titer) of the anti-DENV
antibodies, and the accessibility of the epitopes targeted
by these antibodies. Here we show that DENV-specific IgM
antibodies likely play a role in neutralization during
primary DENV infections and show a correlation between
serum avidity and neutralization capacity in secondary
DENV infections, with greater avidity to a previously
infecting DENV serotype as compared to the current
infecting DENV serotype in the early phases of infection,
switching over time to the opposite situation.
Dengue Neutralization and Serum Avidity
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N172 to the amount of DENV3, we used a pan-DENV MAb, 2H12
(gift from G. Screaton, Imperial College, UK) [40]. Serial dilutions
of DENV2 and the 1:300 dilution of DENV3 were coated and
incubated with 1 mg/mL of 2H12 MAb. The 1:300 dilution of
DENV2 (3.66104 pfu/ml) yielded the same OD as the 1:300
DENV3 and was used thereafter. To determine serum IgG avidity,
plates were coated with whole virus and incubated with heat-
inactivated diluted serum samples (1:100) in triplicate, then washed
with urea or PBS for 10 min before adding the secondary biotin-
conjugated Ab (donkey anti-human IgG, 1:1,000), streptavidin-AP
conjugate (1:1,000), and PnPP substrate [9]. Using samples from the
same study population, we previously optimized the amount of urea
to be used, and 6M urea for 1u DENV infections and 9M urea for 2u
DENV infections yielded the best results for analyzing serum avidity
to DENV over time [9]. To measure serum IgM avidity, a donkey
anti-human IgM, Fc-fragment-specific MAb (1:1,000, Jackson
ImmunoResearch) was used as secondary Ab. For acute-phase
samples, days 4–6 post-onset of symptoms were chosen. Background
levels were measured with dengue-negative human sera. For each
sample, avidity was calculated as percentage of IgG or IgM bound
by dividing the background-adjusted OD after urea washes by the
adjusted OD after PBS washes.
Quality control criteria included: background ,0.2 OD, WHO
polyvalent serum positive control .5X background OD, and
WHO positive control of each plate within the mean +/21 SD of
control plate. The control plate was coated with either DENV2 or
DENV3 and incubated with WHO polyvalent serum; half the
plate was washed with urea (6M or 9M), while the second half was
washed with PBS. The mean and SD for the WHO polyvalent
positive control was calculated for each urea concentration and
each virus as follows:
meanurea=meanPBSð Þ+ meanurea=meanPBSð Þ




The data were stratified by 1u and 2u infection status for
analysis, and gender was evaluated as a possible modifier.
Geometric mean total Ab titer, percentage avidity, and NT50
were compared using the two-sided Wilcoxon Signed Rank test to
detect differences between the following time-points: acute and
convalescent; convalescent and 3 m; 3 m and 6 m; and 6 m and
18 m. Geometric mean Ab titer, avidity, and NT50 were also
compared by infection status at each time-point using the
Wilcoxon Signed Rank test. Bivariate correlations between NT50
and Ab titer or NT50 and avidity were estimated using the
Spearman correlation coefficient at each time-point. To test for
differences in avidity, NT50, and Ab titer by clinical signs of
dengue severity (vascular leak, hypotensive shock, compensated
shock, cutaneous bleeding, hemoconcentration and mucosal
bleeding [37]), two-sided Wilcoxon Signed Rank tests were used
to compare the geometric mean NT50, total Ab titer and avidity at
each time-point, stratifying by immune status. An alpha of p,0.05
was used for statistical significance testing. Calculations were
performed in SAS Version 9.2 (The SAS Institute, Cary, NC).
Results
Study participants
Between August 1, 2010, and January 31, 2011, 216 patients
were enrolled for suspected dengue at the National Pediatric
Reference Hospital, HIJMR. Twelve patients were excluded from
analysis: one patient dropped out of the study after enrollment and
11 patients had an undetermined dengue diagnostic result. Of the
204 patients who were followed, 108 patients (52.9%) were
laboratory-confirmed as DENV3-positive by RT-PCR and/or
virus isolation and were included in this analysis (Table S1). Of
these, 61 (56.5%) were 1u and 47 (43.5%) were 2u DENV
infections (Table 1). Of note, disease severity was relatively low in
the 2010–2011 season, with 27 (25.0%) DHF/DSS cases (Table 1)
[2]. In the absence of a pre-infection sample, and while we cannot
exclude previous DENV1 infections, we hypothesized that most
children with 2u DENV infections were previously infected with
DENV2, which was the predominant serotype circulating in
previous years [28,29]. Thus, we used DENV2 as a representative
previously infecting serotype in our analysis.
Longitudinal analysis of DENV-specific serum
neutralization
We measured the DENV-specific neutralization capacity of
patient sera from 1u and 2u DENV3 infections against DENV3,
the current infecting serotype, and against DENV2, a represen-
tative previously infecting serotype, in 2u infections. Using a flow
cytometry-based assay, NT50 was determined at acute, convales-
cent, 3 m, 6 m, and 18 m time-points (Table S2). The NT50
against DENV3 peaked at convalescence in both 1u and 2u cases,
with significantly higher titers detected in 2u cases (Figure 1A–B).
In 1u infections, we observed a significant increase in NT50 from
the acute to convalescent phase (p,0.001) followed by a significant
drop from convalescence to 3 m post-onset of symptoms
(p,0.0001), further decreasing at 6 m (p,0.0001) (Figure 1A).
For 2u infections, we noted a similar pattern (p,0.0001 for each
pair of adjacent time-points) (Figure 1B). In addition, for 2u
Table 1. Characteristics of patients enrolled in the hospital-
based study during the 2010–2011 dengue season in
Managua, Nicaragua.
Indicator N % Mean age ± SD
Participants 108 100 8.463.6
Gender
Female 52 48.2 8.263.7
Male 56 51.8 8.763.7
Disease classification
Dengue Fever (DF) 80 74.8 8.163.6
Dengue Hemorrhagic Fever (DHF) 25 23.4 9.164.0
Dengue Shock Syndrome (DSS) 2 1.9 10.760.4
Immune status
Primary infection 61 56.5 6.963.6
Secondary infection 47 43.5 10.462.8
Clinical sign (proportion with sign present)*
Compensated shock 21 19.4 8.563.5
Hypotensive shock 6 5.6 8.463.8
Vascular leak 71 65.7 7.963.8
Cutaneous bleeding 83 77.8 8.263.6
Mucosal bleeding 13 12.0 9.663.0
Hemoconcentration 3 2.8 9.064.7
*Defined as in Narvaez et al [32].
doi:10.1371/journal.pntd.0002274.t001
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infections, we measured the DENV2-specific neutralization
capacity of the serum, which showed a similar trend (Figure 1C).
Longitudinal analysis of DENV-specific serum avidity
We measured DENV-specific IgG serum avidity to DENV3 and
DENV2 and DENV-specific IgM serum avidity to DENV3 using
a modified ELISA with urea washes [22,23]. Avidity was defined
as the percentage (%) of IgG or IgM that remained bound after the
urea washes. In 1u DENV3 infections, we observed a large
increase in IgG serum avidity to DENV3 between convalescence
and 3 m post-onset of symptoms (p,0.0001) and a further rise
between 3 and 6 months (p = 0.017) and between 6 and 18 months
(p = 0.003) post-onset of symptoms (Figure 2A, Table S2). IgM
serum avidity to DENV3 in 1u DENV3 acute samples revealed a
mean % IgM bound of 47.9 (SD612.3). In 2u DENV infections,
we observed a significant increase in IgG serum avidity to DENV3
between the acute and convalescent phase (p,0.0001), but no
further rise at later time-points (Figure 2B, Table S2).
Measuring the avidity of the same 2u infections to DENV2, a
likely previously infecting serotype, we observed significantly
higher levels of % IgG bound to DENV2 than DENV3 in the
acute phase (p = 0.0004) (Figure 2C, 3A). However, due to the
increase in avidity to DENV3 in the convalescent phase, no
significant difference in avidity was detectable between the two
serotypes (p = 0.22) (Figure 3B). Subsequently, at the 3 m, 6 m,
and 18 m time-points, a shift occurred to significantly higher
avidity against DENV3, the currently infecting serotype, than
against DENV2 (p,0.0001, p = 0.0004, and p = 0.001, respec-
tively) (Figure 3C–E). Of note, the IgG serum avidity remained
high for 1u DENV cases, while it declined for 2u cases after the
convalescent time-point (Figure 2).
Correlation between DENV-specific total antibody titer,
avidity and neutralization capacity of serum
The ability of serum to neutralize a virus can depend on Ab
concentration and/or serum avidity [32], among other parame-
ters. During 1u DENV infections, a positive correlation between
IgM serum avidity to DENV3 and DENV3-specific NT50 in the
acute phase was observed (Figure 4), suggesting contribution of
DENV-specific IgM Abs to early virus neutralization. We also
observed a positive correlation between IgG serum avidity to
DENV3 and NT50 to DENV3 in the acute phase of 2u DENV3
cases and at the 3 m time-point (Figure 4, Table 2). Due to the
slow kinetics of affinity maturation, these highly avid IgG are most
likely secreted by pre-existing MBCs, suggesting the contribution
of DENV cross-reactive Ab to virus neutralization. Moreover, a
correlation was observed between DENV-specific total Ab titers
and NT50 against DENV3 in the acute phase of 2u DENV3
infections (Table 2). Interestingly, positive correlations were noted
between DENV2-specific NT50 and % IgG bound to DENV2
from the acute phase until 18 m post-infection (Figure S1, Table 2).
Lastly, a positive correlation was observed between DENV2-
specific NT50 and IgG serum avidity to DENV3 at acute and
convalescent time-points (Figure S2, Table 2).
Association with disease severity and clinical signs of
severity
NT50, total Ab titer, and % IgG bound were compared between
patients with and without the following clinical signs, stratified by
immune status: compensated shock, hypotensive shock, vascular
leak, cutaneous bleeding, mucosal bleeding, and hemoconcentra-
tion (defined as in [33]). No difference was observed in the mean
NT50, total Ab titer, or % IgG at any time-point examined among
Figure 1. Longitudinal analysis of DENV-specific serum neu-
tralizing Abs. A. DENV3-specific NT50 of serum day 4–6 (acute), day
14–28 (convalescent), 3 m, 6 m and 18 m post-onset of symptoms in 1u
DENV3 infections. Longitudinal serum samples were analyzed via a flow
cytometry-based neutralization assay. The mean +/2 SD as well as the
25th and 75th percentiles of NT50 are displayed. B. DENV3-specific NT50
of serum day 6 (acute), day 14–28 (convalescent), 3 m, 6 m and 18 m
post-onset of symptoms in 2u DENV3 infections. Longitudinal serum
samples were analyzed as described in Figure 1A. C. DENV2-specific
NT50 of serum day 6 (acute), day 14–28 (convalescent), 3 m, 6 m and
18 m post-onset of symptoms in 2u DENV3 infections. Longitudinal
serum samples were analyzed as described in Figure 1A. Diamonds,
mean; middle line, median; upper and lower boundary of the box, intra-
quartile range (IQR; 25th to 75th percentile); whiskers, range of values
that are outside of the IQR but are close enough not to be considered
outliers (within #1.5*IQR); empty circles: outliers .1.5*IQR.
doi:10.1371/journal.pntd.0002274.g001
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1u or 2u infections. When using the WHO classification (DF vs.
DHF/DSS), patients classified as DF did not demonstrate a
statistically significant difference in mean NT50 or % IgG bound
compared to those classified as DHF/DSS (stratified by immune
status), except for convalescent % IgG bound to DENV3 in 1u
DENV3 infections, with 41.268.3 for DF and 53.4614.2 for
DHF/DSS (p = 0.005). A significant difference in total Ab titer was
observed between 1u DF and DHF/DSS cases at the convalescent
time-point (p = 0.035) with a higher Ab titer observed in more
severe cases (248.7679.9 vs. 109.5630.9).
Discussion
A better understanding of protective immune responses to
natural DENV infections is critical for the development of safe and
effective vaccines and for defining robust correlates of protection
for vaccine trials. Protection from DENV infection and/or disease
may depend on DENV-specific serum neutralization and thus may
be associated with DENV-specific Ab titer and DENV-specific
serum avidity. However, several questions remained unanswered,
such as the role of IgM Abs and whether serum avidity correlates
with serum neutralization. Using our longitudinal sample series
from our hospital-based study, we show for the first time that
DENV-specific neutralization titers peak in the convalescent phase
and then decrease over time in both 1u and 2u DENV3 infections.
We also observed increasing DENV3-specific avidity between the
convalescent phase and 3 m post-infection in 1u DENV3 cases and
between acute and convalescent phases in 2u DENV3 infections.
In addition, we detected higher avidity against a heterologous,
potentially previously infecting serotype (DENV2) in the acute
phase of 2u DENV3 infections, while avidity was higher against
the current infecting serotype at later time-points (3–18 m).
Finally, we show for the first time a correlation between serum
avidity and serum neutralization titers in the context of DENV
infection, and specifically demonstrate that serotype-specific
neutralizing titers correlate with serum IgM avidity in 1u acute
DENV infections and with serum IgG avidity in 2u DENV
infections.
In this study, we show that the DENV-specific NT50 increases
from the acute to the convalescent phase in both 1u and 2u
infections, with a higher NT50 in 2u cases. Whereas in 1u
infections, naı̈ve B cells are stimulated and IgG Abs are detected
only in the convalescent phase, cross-reactive memory B cells are
reactivated during 2u cases, inducing a rapid increase in DENV-
specific IgG Ab in serum [41]. Neutralization is achieved when
enough Abs bind to accessible epitopes of DENV, preventing
binding to target cells or fusion of the viral and endosomal
membranes and subsequent release of viral RNA into the
cytoplasm of susceptible cells [42]. At later time-points (3–18 m),
a decrease in NT50 was observed, as previously shown with DENV
and other viruses [41,43].
In 1u DENV infections, we observed an increase in serum IgG
avidity to DENV3 between convalescent phase and 3 m, reflecting
affinity maturation of Abs. MBCs and LLPCs develop from naı̈ve
B cells and undergo affinity maturation and selection during the
first 3 m after infection. As only clones with the highest avidity
survive long-term, this leads to a higher mean IgG avidity over
time [7,8]. In contrast, in 2u DENV infections, we observed an
increase in serum IgG avidity to DENV3 earlier, between the
acute and convalescent phase, which cannot be explained by
affinity maturation of newly activated DENV3-specific B cells.
Rather, this suggests that cross-reactive Abs secreted by pre-
existing MBCs contribute to the early increase in avidity during 2u
heterotypic DENV infections.
Figure 2. Longitudinal analysis of DENV-specific serum IgG and
IgM avidity. A. IgG serum avidity to DENV3 day 14–28 (convalescent),
3 m, 6 m and 18 m post-onset of symptoms in 1u DENV3 infections.
Longitudinal serum samples were tested for DENV-specific avidity using
a modified ELISA with 6M urea washes against DENV3 strain N7236
virions. The mean +/2 SD as well as the 25th and 75th percentiles of %
IgG bound are displayed. B. IgG serum avidity to DENV3 day 6 (acute),
day 14–28 (convalescent), 3 m, 6 m and 18 m post-onset of symptoms
in 2u DENV3 infections. Longitudinal serum samples were analyzed as in
Figure 2A. C. DENV3-specific IgG serum avidity day 6 (acute), day 14–28
(convalescent), 3 m, 6 m and 18 m post-onset of symptoms in 2u
DENV3 infections. Longitudinal serum samples were analyzed as in
Figure 2A. Diamonds, mean; middle line, median; upper and lower
boundary of the box, intra-quartile range (IQR; 25th to 75th percentile);
whiskers, range of values that are outside of the IQR but are close
enough not to be considered outliers (#1.5*IQR); empty circles, outliers
.1.5*IQR.
doi:10.1371/journal.pntd.0002274.g002
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In previous studies, we found significantly higher serum IgG
avidity directed to a possible previously infecting DENV serotype
(DENV2) as opposed to the current infecting serotype (DENV3) in
the acute phase of 2u DENV3 infections [9]. Here, we confirm
these findings and show that subsequently, serum IgG avidity
against the current infecting serotype increases over time such that
avidity to the current infecting serotype is greater than that to the
previous infecting serotype 3–18 m post-infection. Serum IgG
avidity to DENV2 decreases at 18 m time-point, possibly as
DENV2-specific LLPCs are displaced from the bone marrow and
replaced by newly generated DENV3-specific LLPCs. LLPC
niches are limited in the bone marrow, and newly formed LLPCs
can replace LLPCs formed during earlier infections [44,45]. The
decrease in serum IgG avidity to DENV3 at the 18 m time-point
could be explained by a strong extra-follicular response induced by
the presence of pre-existing anti-DENV Abs in 2u infections,
inhibiting the germinal center response and thus inhibiting a
strong long-term immunity to the current infecting serotype,
DENV3 [46].
Correlation between serum avidity and serum neutralization
has been reported for measles, HIV and cytomegalovirus
infections [47–49]. We analyzed here whether DENV-specific
serum avidity and total Ab titer correlate with DENV-specific
neutralization. During 1u DENV infections, neither IgG serum
avidity to DENV3 nor DENV-specific total Ab titer correlated
with DENV3-specific NT50. Rather, the NT50 correlated with
IgM serum avidity to DENV3 in the acute phase of 1u DENV3
infections, showing that highly avid IgM Abs are also highly
neutralizing and suggesting that IgM Abs play an important role in
DENV-specific serum neutralization. In contrast, in the acute
phase of 2u DENV infections, DENV3-specific NT50 correlated
with IgG serum avidity to DENV3. Because of the rapid kinetics of
appearance of IgG Abs in a 2u DENV infection and the slow
affinity maturation process, these highly avid IgG Abs are most
likely secreted by MBCs formed during the previous infection
rather than by newly-activated naı̈ve B cells. This suggests that
cross-reactive Abs contribute to neutralization of acute 2u DENV
infections. This is consistent with the isolation of strongly
neutralizing cross-reactive MAbs from 2u DENV infections (S.
Smith, J. Crowe, R. de Alwis, A. de Silva & E. Harris, unpublished
data). IgG serum avidity to DENV2 and DENV2-specific NT50
correlated at all time-points, suggesting that affinity maturation
after the 1u infection contributes to strengthening the neutralizing
activity of serum Abs. We also observed a correlation between IgG
serum avidity to DENV3 and DENV2-specific NT50, further
supporting the relation between cross-reactive Abs and neutrali-
zation. Furthermore, a positive correlation between DENV-
specific total Ab titer and DENV3-specific NT50 in acute 2u
Figure 3. IgG serum avidity to DENV2 versus DENV3 over time. % IgG bound to DENV2 and DENV3 was compared at day 6 (acute) (A), day
14–28 (convalescent) (B), 3 m (C), 6 m (D), and 18 m (E) post-onset of symptoms in 2u DENV3 infections for every patient and is shown as connected
dots. The Wilcoxon Rank Sum test was used to compare % IgG bound in serum to DENV2 and DENV3 Nicaraguan viruses.
doi:10.1371/journal.pntd.0002274.g003
Figure 4. Correlations between DENV-specific serum neutral-
izing titers and serum avidity over time. Correlation between
DENV3-specific NT50 and IgM avidity to DENV3 in the acute phase of 1u
DENV3 infections (A); correlation between DENV3-specific NT50 and IgG
avidity to DENV3 in the acute phase of 2u DENV3 infections (B); and
correlation between DENV3-specific NT50 and IgG avidity to DENV3 3 m
post-onset of symptoms in 2u DENV3 infections (C). Spearman’s rank
correlation coefficient (r) and p-value were calculated between the
pairs of NT50 with % IgM and % IgG bound, respectively.
doi:10.1371/journal.pntd.0002274.g004
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DENV infections was found, showing that a greater amount of
Abs correlates with neutralization activity.
Since dengue disease severity may be associated with sub-
neutralizing (enhancing) concentrations of DENV-specific Abs
[50,51], we analyzed NT50 titers and IgG serum avidity among
DF vs. DHF/DSS patients and among cases with different clinical
signs of severity but did not find many significant differences.
However, this could be due to the relatively low disease severity in
the 2010–2011 epidemic in Nicaragua and thus the small sample
size of DHF/DSS. Finally, pre-infection samples are not available
through this hospital-based study; thus, we chose one likely
previous infecting serotype (DENV2) to analyze in this group of
patients. Analysis of samples collected from documented sequen-
tial infections in our long-term prospective dengue cohort study
will enable more precise investigation of cross-reactive Abs in 2u
DENV infections.
Overall, this study showed that IgM and cross-reactive IgG
contribute to neutralization during acute DENV infections. To
further support these results, we are conducting additional analyses
of the DENV-specific serum neutralization capacity, including: 1)
the use of b-mercaptoethanol to chemically deplete IgM Abs and
2) the use of DENV virions to deplete heterologous serotype cross-
reactive Abs. While cross-reactive serum avidity dominates the
acute 2u DENV response, avidity to the current infecting serotype
becomes dominant over time. Significant correlations were
observed between neutralizing Ab titers and serum avidity to
both the current and a heterotypic serotype. Future studies will
address the relation of avidity and NT50 to infection outcome
(symptomatic vs. inapparent) and to disease severity. The
unexpected results from the first proof-of-concept dengue live
attenuated vaccine efficacy trial (Phase 2b) that were recently
published [52] highlight the critical need to better understand the
immune response to natural DENV infections and vaccine
candidates and to identify robust correlates of protection. We
believe that measurement of DENV-specific serum avidity should
be integrated into evaluation of future vaccine trials and applied
more broadly to the study of the immune response to DENV after
natural infections.
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